Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases.
2 sources
The release calls it a financing round but gives no series or stage label; no lead investor is identified.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $102M | 2025-04-03 | not stated | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources The release calls it a financing round but gives no series or stage label; no lead investor is identified. | ||||